Acute Respiratory Distress Syndrome

Respiratory·MeSH: Respiratory Distress Syndrome

Prevalence

0.1 / 100K

13 drugs in development·11 companies·14 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Phase 2(3)

Drug	Company
allogeneic invariant natural killer t cells	ImmunityBio, Inc. (IBRX)
av-001	Axsome Therapeutics, Inc. (AXSM)
nogapendekin alfa-inbakicept	ImmunityBio, Inc. (IBRX)

Preclinical(4)

Drug	Company
cb5064 analogs	COHBAR, INC. (COBU)
hemoglobin-based artificial oxygen carriers	SANGUI BIOTECH INTERNATIONAL INC (SGBI)
php-303	Peak Bio, Inc. (PKBO)
sbt102	SANGUI BIOTECH INTERNATIONAL INC (SGBI)

Unknown(2)

Drug	Company
Allogeneic MSC therapy platform	BioCardia, Inc. (BCDA)
NoveCite	Citius Pharmaceuticals, Inc. (CTXR)

Phase 1/Phase 2(1)

Drug	Company
stsa-1002	Eiger BioPharmaceuticals, Inc. (EIGR)

BioSniper tracks 13 drugs in development for Acute Respiratory Distress Syndrome across 11 companies.

There are 14 clinical trials targeting Acute Respiratory Distress Syndrome tracked by BioSniper.

The estimated prevalence of Acute Respiratory Distress Syndrome is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.